Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

William Cushman, Richard H. Grimm, Jeffrey A. Cutler, Gregory W. Evans, Sarah Capes, Marshall A. Corson, Laurie S. Sadler, Michael H. Alderman, Kevin Peterson, Alain Bertoni, Jan N. Basile

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

The Action to Control Cardiovascular Disease in Diabetes (ACCORD) blood pressure trial is an unmasked, open-label, randomized trial with a sample size of 4,733 participants. This report describes the rationale, design, and methods of the blood pressure interventions in ACCORD. Participants eligible for the blood pressure trial are randomized to 1 of 2 groups with different treatment goals: systolic blood pressure <120 mm Hg for the more intensive goal and systolic blood pressure <140 mm Hg for the less intensive goal. The primary outcome measure for the trial is the first occurrence of a major cardiovascular disease (CVD) event, specifically nonfatal myocardial infarction or stroke, or cardiovascular death during a follow-up period ranging from 4-8 years. The ACCORD blood pressure trial should provide the first definitive clinical trial data on the possible benefit of treating to a more aggressive systolic blood pressure goal in reducing CVD events in patients with diabetes mellitus.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume99
Issue number12 SUPPL.
DOIs
StatePublished - Jun 18 2007
Externally publishedYes

Fingerprint

Blood Pressure
Cardiovascular Diseases
Myocardial Infarction
Sample Size
Diabetes Mellitus
Outcome Assessment (Health Care)
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. / Cushman, William; Grimm, Richard H.; Cutler, Jeffrey A.; Evans, Gregory W.; Capes, Sarah; Corson, Marshall A.; Sadler, Laurie S.; Alderman, Michael H.; Peterson, Kevin; Bertoni, Alain; Basile, Jan N.

In: American Journal of Cardiology, Vol. 99, No. 12 SUPPL., 18.06.2007.

Research output: Contribution to journalArticle

Cushman, W, Grimm, RH, Cutler, JA, Evans, GW, Capes, S, Corson, MA, Sadler, LS, Alderman, MH, Peterson, K, Bertoni, A & Basile, JN 2007, 'Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial', American Journal of Cardiology, vol. 99, no. 12 SUPPL.. https://doi.org/10.1016/j.amjcard.2007.03.005
Cushman, William ; Grimm, Richard H. ; Cutler, Jeffrey A. ; Evans, Gregory W. ; Capes, Sarah ; Corson, Marshall A. ; Sadler, Laurie S. ; Alderman, Michael H. ; Peterson, Kevin ; Bertoni, Alain ; Basile, Jan N. / Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. In: American Journal of Cardiology. 2007 ; Vol. 99, No. 12 SUPPL.
@article{b1d3528161e64582b752d3e5f6391b43,
title = "Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial",
abstract = "The Action to Control Cardiovascular Disease in Diabetes (ACCORD) blood pressure trial is an unmasked, open-label, randomized trial with a sample size of 4,733 participants. This report describes the rationale, design, and methods of the blood pressure interventions in ACCORD. Participants eligible for the blood pressure trial are randomized to 1 of 2 groups with different treatment goals: systolic blood pressure <120 mm Hg for the more intensive goal and systolic blood pressure <140 mm Hg for the less intensive goal. The primary outcome measure for the trial is the first occurrence of a major cardiovascular disease (CVD) event, specifically nonfatal myocardial infarction or stroke, or cardiovascular death during a follow-up period ranging from 4-8 years. The ACCORD blood pressure trial should provide the first definitive clinical trial data on the possible benefit of treating to a more aggressive systolic blood pressure goal in reducing CVD events in patients with diabetes mellitus.",
author = "William Cushman and Grimm, {Richard H.} and Cutler, {Jeffrey A.} and Evans, {Gregory W.} and Sarah Capes and Corson, {Marshall A.} and Sadler, {Laurie S.} and Alderman, {Michael H.} and Kevin Peterson and Alain Bertoni and Basile, {Jan N.}",
year = "2007",
month = "6",
day = "18",
doi = "10.1016/j.amjcard.2007.03.005",
language = "English (US)",
volume = "99",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

AU - Cushman, William

AU - Grimm, Richard H.

AU - Cutler, Jeffrey A.

AU - Evans, Gregory W.

AU - Capes, Sarah

AU - Corson, Marshall A.

AU - Sadler, Laurie S.

AU - Alderman, Michael H.

AU - Peterson, Kevin

AU - Bertoni, Alain

AU - Basile, Jan N.

PY - 2007/6/18

Y1 - 2007/6/18

N2 - The Action to Control Cardiovascular Disease in Diabetes (ACCORD) blood pressure trial is an unmasked, open-label, randomized trial with a sample size of 4,733 participants. This report describes the rationale, design, and methods of the blood pressure interventions in ACCORD. Participants eligible for the blood pressure trial are randomized to 1 of 2 groups with different treatment goals: systolic blood pressure <120 mm Hg for the more intensive goal and systolic blood pressure <140 mm Hg for the less intensive goal. The primary outcome measure for the trial is the first occurrence of a major cardiovascular disease (CVD) event, specifically nonfatal myocardial infarction or stroke, or cardiovascular death during a follow-up period ranging from 4-8 years. The ACCORD blood pressure trial should provide the first definitive clinical trial data on the possible benefit of treating to a more aggressive systolic blood pressure goal in reducing CVD events in patients with diabetes mellitus.

AB - The Action to Control Cardiovascular Disease in Diabetes (ACCORD) blood pressure trial is an unmasked, open-label, randomized trial with a sample size of 4,733 participants. This report describes the rationale, design, and methods of the blood pressure interventions in ACCORD. Participants eligible for the blood pressure trial are randomized to 1 of 2 groups with different treatment goals: systolic blood pressure <120 mm Hg for the more intensive goal and systolic blood pressure <140 mm Hg for the less intensive goal. The primary outcome measure for the trial is the first occurrence of a major cardiovascular disease (CVD) event, specifically nonfatal myocardial infarction or stroke, or cardiovascular death during a follow-up period ranging from 4-8 years. The ACCORD blood pressure trial should provide the first definitive clinical trial data on the possible benefit of treating to a more aggressive systolic blood pressure goal in reducing CVD events in patients with diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=34250730722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250730722&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.03.005

DO - 10.1016/j.amjcard.2007.03.005

M3 - Article

VL - 99

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12 SUPPL.

ER -